IPSC0013, TMEM175 M393T homozygous correction
The cell line is not validated yet.
CBIGi009-A-1
General
Cell Line |
|
| hPSCreg name | CBIGi009-A-1 |
| Cite as: | CBIGi009-A-1 |
| Alternative name(s) |
IPSC0013, TMEM175 M393T homozygous correction
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi009-A (IPSC0012, TMEM175 M393T homozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi007-A-1 (IPSC0009, TMEM175 Q65Q homozygous correction) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi007-A-2 (IPSC0010, TMEM175 P65P homozygous disease) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi009-B (TMEM175 M393T homozygous (CBIGi009), IPSC0033) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi007-A (IPSC0008, TMEM175 Q65P heterozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi001-A-25 (IPSC0097, TMEM175-KO/AIW002-02) EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease CBIGi013-A-1 (LRRK2 M1646T correction, IPSC0018) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi027-A-1 (IPSC0039, LRRK2 G2385R (CBIGi027) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease CBIGi039-A-1 (IPSC0051, LRRK2 R1441H(CBIGi039-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi041-A-1 (IPSC0054, GBA L444P (CBIGi041-A) correction) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi042-A-1 (GBA E326K (CBIGi042-A) correction, IPSC0056) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi044-A-1 (IPSC0059, LRRK2 N551K (CBIGi044-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi044-A-2 (IPSC0060, LRRK2 R1398H (CBIGi044-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease |
| Last update | 30th July 2025 |
| Notes | Isogenic control for CBIGi009-A. |
| User feedback | |
Provider |
|
| Generator | Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) |
| Distributors | |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA117843865 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA117843857 |
Ethics
Also have a look at the ethics information for the parental line
CBIGi009-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CBIGi009-A.
|
|
| Passage number reprogrammed | P15 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
| Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal 46, XX
Passage number: P15
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.